Novartis: 1996 – 2013 Dr Daniel Vasella was the first CEO of the newly merged company. Vasella was hired by Sandoz back in 1988 and remained there until 1992 when he was promoted to CEO of its ...

Novartis is just months away from filing for approval of oral BTK inhibitor remibrutinib as a treatment for chronic spontaneous urticaria – also known as chronic hives – after reporting long ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

At Novartis, we innovate, develop and operate on a vast scale. You can be part of it. Join our creative community of professionals and you will find opportunities to make an unprecedented impact – on ...

Novartis India Ltd., incorporated in the year 1947, is a Small Cap company (having a market cap of Rs 2,666.61 Crore) operating in Pharmaceuticals sector. Novartis India Ltd. key Products/Revenue ...

At Novartis, our continued success depends on our ability to proactively detect and manage risk. Therefore, risk management is an integral element of our Ethics, Risk and Compliance program. As part ...